Form 4: Iovance Biotherapeutics Chief Medical Officer Reports Stock Transactions

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Summary

• Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 2, 2024, 3,906 restricted stock units (RSUs) vested, converting into common stock.
• The company withheld 1,982 shares to cover tax obligations at a price of $9.07 per share.
• After the tax withholding, Mr. Finckenstein's direct holdings of common stock decreased by 1,982 shares to 62,651 shares.
• Mr. Finckenstein still holds 19,533 unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions, which is neither positive nor negative in itself.

Industry Context

This is a routine filing for a company officer and is typical for companies that use stock-based compensation.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
• The vesting of restricted stock units and subsequent tax withholding are common forms of executive compensation across the biotechnology industry.
• The transaction is similar to those of other executives at comparable companies who receive equity as part of their compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in insider ownership.

Key Dates

Keywords

Form 4, insider trading, stock transaction, restricted stock units, IOVA, Iovance Biotherapeutics, beneficial ownership, Chief Medical Officer